Filing Analysis
Kalaris Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. The meeting resulted in the election of three Class III directors, approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Election of Napoleone Ferrara, M.D., David Hallal, and Leone Patterson as Class III directors for three-year terms expiring in 2029.
- Approval of named executive officer compensation on a non-binding advisory basis (15,852,844 votes For vs 495,763 Against).
- Stockholders recommended that future advisory votes on executive compensation be held every year (16,336,117 votes for 'One Year').
- Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Kalaris Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a routine update on the company's operations and financial condition.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026
- Press release issued on May 12, 2026
- Filing submitted under Item 2.02 (Results of Operations and Financial Condition)
- Information is furnished and not deemed filed for Section 18 purposes
Kalaris Therapeutics announced the resignation of CFO Matthew Gall, effective April 14, 2026. Brett Hagen, the company's current Chief Accounting Officer, will assume the role of Principal Financial Officer.
🚩 Red Flags
- Short notice period (6 days) between the resignation notification and the effective separation date.
- The company is a micro-cap biotech where CFO turnover can often precede capital raises or strategic shifts.
📋 Key Facts
- Matthew Gall notified the company of his resignation as CFO on April 8, 2026.
- The resignation is effective April 14, 2026, representing a short notice period of six days.
- Brett Hagen, 53, has been appointed as the Principal Financial Officer effective April 14, 2026.
- Hagen has served as the company's Chief Accounting Officer since January 2019.
- No changes were made to Hagen's compensatory plans in connection with the appointment.
Kalaris Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025. The results were released via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 17, 2026, reporting on the fiscal year ended December 31, 2025.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results is included as Exhibit 99.1.
- The company is listed on The Nasdaq Global Market under the symbol KLRS.
Kalaris Therapeutics furnished an updated corporate presentation for the Leerink Partners Global Healthcare Conference on March 9, 2026. The presentation provides updated clinical timelines for its lead candidate TH103 and revised cash runway guidance.
🚩 Red Flags
- Forward-looking statements highlight risks related to the inability to obtain sufficient additional capital to advance product candidates
📋 Key Facts
- Updated timelines for reporting data from the Phase 1b/2 multi-ascending dose clinical trial of TH103
- Updated timelines for initiating Phase 3 clinical development of TH103
- Provision of updated cash runway guidance
- Presentation scheduled for use at the Leerink Partners Global Healthcare Conference